Sandoz, Stada and Viatris Are Among Firms Announcing New Appointments
• By David Wallace
Generate a summary of this article
Listen to this article
The start of 2023 has seen a number of firms across the off-patent industry announce management changes, with multiple appointments at Sandoz, a new CFO at Stada, a fresh CSO at Mallinckrodt, new generics leadership at Orion and board changes at Viatris and EuroAPI.
The new year has brought new faces at a number of firms • Source: Shutterstock
Sandoz has kicked off the new year with multiple new executive appointments, including naming Hannes Woerner as head of global operations for its anti-infectives business.
Having previously served as global supply-chain head for the Novartis generics and biosimilars division, Woerner “brings in his new role...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.